실시간 바이오 인텔리전스 · ADC · CGT

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

9,268+프로그램
35+FDA 승인
4,079+모집 중
ADC 1068·Antibody 5456·CGT 2744차세대 추천 →·Data Tier →
9268프로그램35FDA 승인
0오늘 방문
572누적 방문
8122갱신 대기S–CData TierS/A/B차세대1068HER2 breast5456Antibody2744CGT→Psoriasis→NSCLC35FDA 승인
피드Data Tier차세대

추천 비교

비교 도구 →
HER2 ADCEnhertu · Kadcyla · RC48CD19 CAR-TYescarta · KymriahPD-1Keytruda · Opdivo다발골수종Darzalex · BlenrepTROP2 ADCTrodelvy · Dato-DXd · SGNectin-4 · TROP2Padcev · Trodelvy건선 IL pathwayStelara · Cosentyx · SkyriziAnti-VEGF (안과)Eylea · LucentisAnti-TNFHumira · EnbrelIL-12/23Stelara · Skyrizi아토피·IL-13Dupixent · Ebglyss혈우병 유전자치료Hemgenix · Roctavian겸상적혈구 CGTCasgevy · Lyfgenia망막·DMD 유전자치료Luxturna · Elevidys

최근 활동

RSS →

빠른 검색 · 이슈 태그

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
다음 갱신 D-12 · 마지막 7월 13일
ADCBiologicstaleSeagen Inc.Phase 2

ladiratuzumab vedotin (ladiratuzumab vedotin)

HER2 Positive Breast Neoplasms; Hormone Receptor Positive Breast Neoplasms · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 34%임상시험 5상태 ACTIVE
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

BCMA-CD19 cCAR T cells (BCMA-CD19 cCAR T cells)

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 5상태 RECRUITING
CGTBiologicstaleTakedaPhase 2

CD19-CAR-T2 Cells (CD19-CAR-T2 Cells)

B Cell Leukemia; B Cell Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 5상태 ACTIVE
ADCBiologicstaleArtiva Biotherapeutics, Inc.Phase 2

AB-201 (AB-201)

Breast Cancer; Gastric Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 DISCONTINUED
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

MK-3120 (MK-3120)

Bladder Cancer · Bladder Cancer

#BladderCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 4상태 RECRUITING
AntibodystaleHoffmann-La RochePhase 2

Rituxumab (Rituxumab)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 95%임상시험 4상태 ACTIVE
AntibodystaleAstraZenecaPhase 3

MEDI4736+Tremelimumab (MEDI4736+Tremelimumab)

Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase3#항체#면역항체+2
효능 ORR 37.4%임상시험 4상태 ACTIVE
CGTBiologicThe Affiliated Hospital of Xuzh…Phase 2

Anti-CD56 CAR T (Anti-CD56 CAR T)

Extranodal NK T Cell Lymphoma; NK-Cell Leukemia · Extranodal NK T Cell Lymphoma

#ExtranodalNKTCellLymphoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 4상태 RECRUITING
ADCBiologicstaleHoffmann-La RochePhase 2

Belvarafenib (Belvarafenib)

Solid Tumors · Solid Tumors

#SolidTumors#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 4상태 RECRUITING
AntibodystaleEli Lilly and CompanyPhase 2

Icrucumab (Icrucumab)

Colon Cancer; Rectal Cancer · Carcinoma of Urinary Tract

#CarcinomaofUrinaryTract#Antibody#Phase2#항체#면역항체+4
효능 ORR 28.8%임상시험 4상태 ACTIVE
CGTBiologicFrontera TherapeuticsPhase 2

FT-003 (FT-003)

Diabetic Macular Edema · Neovascular Age-related Macular Degenera

#NeovascularAge-relatedMacularDeg#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 4상태 RECRUITING
AntibodystaleRegeneronPhase 2

VV1 + Cemiplimab (VV1 + Cemiplimab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 4상태 RECRUITING
AntibodystaleBiogenPhase 2

Natalizumab (Natalizumab)

Crohn's Disease · Multiple Sclerosis, Relapsing-Remitting

#MultipleSclerosisRelapsing-Remit#Antibody#Phase2#항체#면역항체+3
효능 ORR 52%임상시험 4상태 ACTIVE
ADCBiologicstaleAbbViePhase 2

IMGN632 (IMGN632)

Blastic Plasmacytoid Dendritic Cell Neoplasm; Myeloproliferative Neoplasm · Blastic Plasmacytoid Dendritic Cell Neop

#BlasticPlasmacytoidDendriticCell#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 RECRUITING
ADCBiologicstaleDay One Biopharmaceuticals, Inc.Phase 1

DAY301 (DAY301)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 4상태 RECRUITING
AntibodyUniversity of CalgaryApproved

ustekinumab (Stelara, Anti-IL12/23 or anti-IL23 - Ustekinumab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Approved#항체#면역항체+2
임상시험 4상태 RECRUITING
ADCBiologicstaleNektar TherapeuticsPhase 2

NKTR-255 (NKTR-255)

Multiple Myeloma; Non-Hodgkin Lymphoma · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 RECRUITING
ADCBiologicstaleMillennium Pharmaceuticals, Inc.Phase 1

MLN0264 (MLN0264)

Advanced Gastrointestinal Malignancies · Advanced Gastrointestinal Malignancies

#AdvancedGastrointestinalMalignan#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 0%임상시험 4상태 ACTIVE
ADCBiologicstaleSanofiPhase 2

SAR439459 (SAR439459)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 RECRUITING
CGTBiologicYake Biotechnology Ltd.Phase 1

APRIL CAR-T cells (APRIL CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 4상태 RECRUITING
AntibodystaleActinium PharmaceuticalsPhase 1

131-I Apamistamab (131-I Apamistamab)

B-ALL; DLBCL · B-ALL

#B-ALL#Antibody#Phase1#항체#면역항체+3
임상시험 4상태 RECRUITING
AntibodyJanssenPhase 2

Amivantamab + FOLFIRI (Amivantamab + FOLFIRI)

RAS/BRAF Wild-type Advanced Colorectal Cancer Patients · RAS/BRAF Wild-type Advanced Colorectal C

#RASBRAFWild-typeAdvancedColorect#Antibody#Phase2#항체#면역항체+4
임상시험 4상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

DLL3-CAR-NK cells (DLL3-CAR-NK cells)

Extensive Stage Lung Small Cell Cancer · SCLC, Extensive Stage

#SCLCExtensiveStage#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 4상태 RECRUITING
CGTBiologicSara V. LatorrePhase 2

ARI-0001 cells (ARI-0001 cells)

Acute Lymphoid Leukemia · Acute Lymphoid Leukemia

#AcuteLymphoidLeukemia#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 4상태 RECRUITING
AntibodystaleBeiGenePhase 1

atezolizumab (Tecentriq, Tislelizumab，atezolizumab or sugemalimab)

NSCLC · NSCLC

#NSCLC#Antibody#Phase1#항체#면역항체+2
임상시험 4상태 RECRUITING

44 / 167 페이지

← 이전다음 →
전체 9,268개 프로그램 보기